Novo Nordisk A/S (NOVO-B.CO) | Investment Case

1. Company Snapshot

1.a. Company Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.It operates in two segments, Diabetes and Obesity care, and Rare Disease.The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases.

The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy.The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics.The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Show Full description

1.b. Last Insights on NOVO

Breaking News: Novo Nordisk A/S recently faced a decline in its stock price, closing at $40.29, a 2.14% decrease from the previous day. The company's potential loss of market share in the obesity treatment market was highlighted by Jim Cramer, who expressed concerns about the company's position relative to Eli Lilly. This comes as Eli Lilly reported strong growth fueled by demand for its weight-loss drugs Mounjaro and Zepbound. Additionally, Eli Lilly raised its full-year sales outlook.

1.c. Company Highlights

Last Price	278
Change Percentage	2.11%
Open	271
Previous Close	272.25
Market Cap ( Millions)	1235154
Volume	4361690
Year High	533.4
Year Low	224.25
M A 50	247.28
M A 200	318.63

FCF Yield	2.35%
Dividend Yield	4.21%
ROE	61.10%
Debt / Equity	67.49%
Net Debt / EBIDTA	65.02%
Price To Book	6.37
Price Earnings Ratio	12.06
Price To FCF	42.61
Price To sales	4.0
EV / EBITDA	8.34

2. Novo Nordisk's 2025 Earnings: A Year of Strong Growth and Innovation

Novo Nordisk delivered a robust financial performance in 2025, with total sales increasing by 10% at constant exchange rates, driven by both its operating units. The company's gross margin decreased to 81%, and operating profit grew by 6% at constant exchange rates. Earnings per share (EPS) came in at 6, beating analyst estimates of 5.83. The company's cash generation was strong, with close to DKK 120 billion generated from operating activities, and around DKK 52 billion returned to shareholders in the form of dividends.

Publication Date: Feb -06

                                    📋 Highlights
                                    Wegovy Sales Surge::
                                                Wegovy generated DKK 28 billion in 2025, reflecting a 134% growth, driven by the FDA-approved oral GLP-1 obesity treatment.
Obesity Market Expansion::
                                                Obesity care sales surged 31% in 2025, outpacing overall sales growth (10%), with 16.6% weight loss efficacy and CV benefits supporting demand.
Shareholder Returns::
                                                Novo Nordisk returned DKK 300 billion to shareholders since 2019, including DKK 52 billion in 2025 dividends and a new DKK 15 billion share buyback program.
R&D Breakthroughs::
                                                CagriSema showed superior A1c reduction and weight loss in Phase III trials, while zenagamtide and UBT251 advanced in Phase II/III for type 2 diabetes.

                                

Segment Performance

The company's obesity care sales surged 31% driven by Wegovy, with sales reaching DKK 28 billion in 2025, growing 134%. GLP-1 sales in diabetes increased by 6%, while insulin sales decreased by 1%. Rare Disease sales grew by 9%. The U.S. operations grew 8%, and International Operations grew 14%. The Wegovy pill, launched on January 5, has seen encouraging early uptake, with over 170,000 people currently on the medication, mostly self-pay.

Innovation Pipeline

Novo Nordisk made significant progress in its R&D pipeline, announcing positive results from the Phase III trial for CagriSema in type 2 diabetes and the Phase II trial for zenagamtide. The company also initiated a Phase Ib/II trial in obesity with a triagonist, GLP-1, GIP amylin targeted agonist. The REDEFINE 4 trial is comparing CagriSema and tirzepatide in an obese population, testing for non-inferiority and then superiority.

Valuation and Outlook

With a P/E Ratio of 12.17 and an ROE of 61.1%, Novo Nordisk's valuation appears reasonable. The company's dividend yield stands at 4.15%, and the free cash flow yield is 4.51%. Analysts estimate next year's revenue growth at 6.9%. Given the company's strong pipeline and growth prospects, the current valuation seems to be fairly priced. The guidance for 2026 reflects expectations for sales growth within International Operations and a decline within U.S. operations due to pricing headwinds.

Guidance and Future Prospects

Novo Nordisk expects adjusted sales growth to be between -5% to -13% at constant exchange rates in 2026, and adjusted operating profit growth to be between -5% to -13% at constant exchange rates. The company is confident in its ability to supply the US market with the Wegovy pill and expects strong demand sustainability due to its 16.6% weight loss benefit and CV benefits. The API build-out is on track, with new facilities coming online this year and in the coming years.

3. NewsRoom

Novo Nordisk Launches Ozempic Pill in U.S.

May -01

Source:

There's Another Twist In The Obesity Pills Showdown — And This One Actually Helps Lilly

May -01

Source:

Novo Launches Ozempic Pills Across 70,000 US Pharmacies

May -01

Source:

Novo Nordisk rolls out Ozempic pill in the U.S.

May -01

Source:

European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week

May -01

Source:

Eli Lilly Stock’s Path To 30% Upside

May -01

Source:

Zoetis Gears Up to Report Q1 Earnings: Is a Beat in the Cards?

May -01

Source: zacks.com

Assessing Novo Nordisk’s (NYSE:NVO) Valuation After A Short Term Share Price Rebound

May -01

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.30%)

6. Segments

Diabetes and Obesity Care

Expected Growth: 10.5%

Growing prevalence of diabetes and obesity drives demand for Novo Nordisk's innovative solutions, such as GLP-1 receptor agonists, which offer improved efficacy and patient outcomes, thereby driving market growth.

Rare Disease

Expected Growth: 7.4%

Novo Nordisk's rare disease treatment and research efforts drive growth, fueled by increasing prevalence of rare diseases and unmet medical needs. The company's strong pipeline and strategic collaborations further support growth.

7. Detailed Products

Ozempic

A glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes

Rybelsus

An oral glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes

Victoza

A glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes

Levemir

A long-acting insulin analog for the treatment of diabetes

NovoEight

A recombinant coagulation factor VIII for the treatment of hemophilia A

NovoSeven

A recombinant coagulation factor VIIa for the treatment of bleeding episodes in patients with hemophilia A or B

8. Novo Nordisk A/S's Porter Forces

Forces Ranking

Threat Of Substitutes

Novo Nordisk A/S faces moderate threat from substitutes, as patients may opt for alternative treatments or lifestyle changes to manage their diabetes. However, the company's innovative products and strong brand recognition mitigate this threat.

Bargaining Power Of Customers

Patients and healthcare providers have limited bargaining power due to Novo Nordisk A/S's strong brand reputation and limited availability of alternative treatments.

Bargaining Power Of Suppliers

Novo Nordisk A/S has a diversified supplier base, reducing dependence on individual suppliers and minimizing the bargaining power of suppliers.

Threat Of New Entrants

The pharmaceutical industry has high barriers to entry, including significant R&D investments and regulatory hurdles, making it difficult for new entrants to compete with Novo Nordisk A/S.

Intensity Of Rivalry

The diabetes treatment market is highly competitive, with several established players, including Eli Lilly, Sanofi, and AstraZeneca, competing with Novo Nordisk A/S for market share.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	20.22%
Debt Cost	3.95%
Equity Weight	79.78%
Equity Cost	4.92%
WACC	4.72%
Leverage	25.34%

11. Quality Control: Novo Nordisk A/S passed 8 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Novartis

A-Score: 6.5/10

Value: 3.0

Growth: 4.2

Quality: 8.3

Yield: 7.5

Momentum: 6.5

Volatility: 9.3

1-Year Total Return ->

GSK

A-Score: 6.3/10

Value: 4.7

Growth: 2.2

Quality: 7.1

Yield: 6.9

Momentum: 9.0

Volatility: 7.7

1-Year Total Return ->

Regeneron Pharmaceuticals

A-Score: 4.9/10

Value: 4.0

Growth: 6.4

Quality: 8.8

Yield: 0.0

Momentum: 4.0

Volatility: 6.3

1-Year Total Return ->

UCB

A-Score: 4.8/10

Value: 1.1

Growth: 5.3

Quality: 7.8

Yield: 1.9

Momentum: 8.5

Volatility: 4.0

1-Year Total Return ->

Novo Nordisk

A-Score: 4.4/10

Value: 3.5

Growth: 8.8

Quality: 8.1

Yield: 5.0

Momentum: 0.0

Volatility: 1.3

1-Year Total Return ->

Vertex Pharmaceuticals

A-Score: 4.0/10

Value: 1.5

Growth: 3.8

Quality: 8.9

Yield: 0.0

Momentum: 3.5

Volatility: 6.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

4.07%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

4.72%

Novo Nordisk A/S - DK0062498333

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on NOVO

1.c. Company Highlights

Better Quality

Expensive

Higher Growth

Earnings Beats

Revenues Beats

Earnings Miss

Strong Momentum

Higher Yield

Revenues Miss

Weak Momentum

2. Novo Nordisk's 2025 Earnings: A Year of Strong Growth and Innovation

Segment Performance

Innovation Pipeline

Valuation and Outlook

Guidance and Future Prospects

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.30%)

6. Segments

Diabetes and Obesity Care

Expected Growth: 10.5%

Rare Disease

Expected Growth: 7.4%

7. Detailed Products

Ozempic

Rybelsus

Victoza

Levemir

NovoEight

NovoSeven

8. Novo Nordisk A/S's Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Novo Nordisk A/S passed 8 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

278.0$

Current Price

278$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA